<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00865280</url>
  </required_header>
  <id_info>
    <org_study_id>PTK 0796 CSSI-0804</org_study_id>
    <nct_id>NCT00865280</nct_id>
  </id_info>
  <brief_title>Study the Safety and Efficacy of PTK 0796 in Patients With Complicated Skin and Skin Structure Infection (CSSSI)</brief_title>
  <acronym>CSSI</acronym>
  <official_title>A Randomized, Evaluator-Blinded, Phase 3 Study to Compare the Safety and Efficacy of PTK 0796 With Linezolid in the Treatment of Adults With Complicated Skin and Skin Structure Infection</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Paratek Pharmaceuticals Inc</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Paratek Pharmaceuticals Inc</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A Phase III trial to demonstrate the safety and efficacy of PTK 0796 in the treatment of
      complicated skin and skin structure infections (cSSSI).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The pharmacologic profile of PTK 0796 in humans suggests that it has the potential to be used
      safely and effectively for this indication. Data from in vitro and animal studies support
      this hypothesis.

      In PTK 0796-CSSI-0804 the safety and efficacy of PTK 0796 in the treatment of cSSSI will be
      compared to an antibiotic approved for this indication by FDA. Initial treatment will be
      administered intravenously with the option for subsequent oral treatment.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Terminated
  </why_stopped>
  <start_date>March 2009</start_date>
  <completion_date type="Actual">April 2010</completion_date>
  <primary_completion_date type="Actual">April 2010</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Clinical success at follow-up</measure>
    <time_frame>4 weeks after enrollment</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>To evaluate safety of dosing regimens.</measure>
    <time_frame>4 weeks after enrollment</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">143</enrollment>
  <condition>Skin Diseases, Infectious</condition>
  <arm_group>
    <arm_group_label>PTK 0796</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>PTK 0796 100mg for injection; PTK 0796 tablet, 150 mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Linezolid</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Gram positive treatment: Linezolid 600 mg tablets and pre-mixed 600 mg IV infusion solution; Gram negative treatment: moxifloxacin 400 mg tablet and moxifloxacin 400 mg IV infusion solution</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PTK 0796</intervention_name>
    <description>PTK 0796 100mg for injection; PTK 0796 tablet 150mg</description>
    <arm_group_label>PTK 0796</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>linezolid</intervention_name>
    <description>For gram positive treatment: Linezolid 600 mg tablets and pre-mixed 600 mg IV infusion solution; For gram negative treatment: Moxifloxacin 400 mg tablets and pre-mixed 400mg IV infusion solution</description>
    <arm_group_label>Linezolid</arm_group_label>
    <other_name>Zyvox™; Avelox™</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients, ages 18 years or older

          -  Is expected to require ≥4 days of IV antibiotic therapy

          -  Has an acute complicated skin and skin structure infection with findings of systemic
             inflammatory response

          -  Female patients must not be pregnant at the time of enrollment and must agree to a
             reliable method of birth control during the study and for 30 days following the last
             dose of study drug

        Exclusion Criteria:

          -  Has received an investigational drug within past 1 month

          -  Has been previously enrolled in this protocol

          -  Has received &gt;24 hr of a potentially effective systemic antibiotic immediately prior
             to study drug

          -  Is nursing
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mary West</last_name>
    <role>Study Director</role>
    <affiliation>Paratek Pharmaceuticals</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Paratek Recruiting Site</name>
      <address>
        <city>Fountain Valley</city>
        <state>California</state>
        <zip>92708</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Parateck Recruiting Site</name>
      <address>
        <city>La Mesa</city>
        <state>California</state>
        <zip>91942</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Paratek Recruiting Site</name>
      <address>
        <city>Oceanside</city>
        <state>California</state>
        <zip>92056</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Paratek Recruiting Site</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Paratek Recruiting Site</name>
      <address>
        <city>San Jose</city>
        <state>California</state>
        <zip>95154</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Parateck Recruiting Site</name>
      <address>
        <city>Columbus</city>
        <state>Georgia</state>
        <zip>31904</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Paratek Recruiting Site</name>
      <address>
        <city>Savannah</city>
        <state>Georgia</state>
        <zip>31406</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 17, 2009</study_first_submitted>
  <study_first_submitted_qc>March 18, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 19, 2009</study_first_posted>
  <disposition_first_submitted>May 20, 2013</disposition_first_submitted>
  <disposition_first_submitted_qc>May 20, 2013</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">May 27, 2013</disposition_first_posted>
  <last_update_submitted>May 20, 2013</last_update_submitted>
  <last_update_submitted_qc>May 20, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 27, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>CSSI</keyword>
  <keyword>Abscess</keyword>
  <keyword>Wound</keyword>
  <keyword>Cellulitis</keyword>
  <keyword>Complicated Skin and Skin Structure Infections (cSSSI)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infection</mesh_term>
    <mesh_term>Skin Diseases</mesh_term>
    <mesh_term>Communicable Diseases</mesh_term>
    <mesh_term>Skin Diseases, Infectious</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Linezolid</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

